Reports
Global Diabetic Retinopathy Treatment Market Size, Forecast: By Type: Proliferative Diabetic Retinopathy, Non-proliferative Diabetic Retinopathy; By Treatment Type: Anti VEGF Drug, Steroid Implants, Laser Surgeries, Vitrectomy; By End Use: Hospitals, Ophthalmic Clinics, Others; Regional Analysis; Competitive Landscape; 2024-2032
Global Diabetic Retinopathy Treatment Market Outlook
The global market for diabetic retinopathy treatment reached a value of about USD 5.7 billion in 2021. The industry is further expected to grow at a CAGR of about 6.70% in the forecast period of 2024-2032 to reach a value of around USD 8.41 billion by 2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to be a Significant Regional Market for Diabetic Retinopathy Treatment
North America is expected to lead the diabetic retinopathy treatment market due to the high market penetration of Eylea, Avastin, and Lucentis, which are anti-VEGF drugs. The market is also expected to grow in this region owing to the supportive reimbursement policies and the increasing prevalence of diabetes in this region. Also, increasing awareness regarding the availability of advanced options for treating diabetic retinopathy also adds to the regional market growth. This market is driven by the availability of modern healthcare infrastructure, favourable government initiatives pertaining to medication research, and high patient and practitioner awareness levels. The market in North America is highly competitive, for instance, Bayer AG is one of the leading companies in the United States that has gained a majority of the market share by introducing superior quality medications for diabetic retinopathy. Therefore, new players are considering the risk of investing in a competitive market in North America.
On the other hand, the Asia Pacific region is expected to expand at a significant growth rate because of the surging geriatric population, high healthcare expenditure, large patient pool, innovation in diagnostic approach, government health insurance policies, and rising disposable income. Diabetes is affecting a huge number of geriatric populations in countries such as China and India post-COVID-19, which is propelling the diabetic retinopathy treatment market in North America. Moreover, the growing usage of Lucentis is expected to drive market growth in this region.
Market Segmentations
Diabetic retinopathy (DR) is the damage caused to the blood vessels in the retina by diabetes mellitus. There are two types of DR: non-proliferative and proliferative or progressed DR. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive tissues in the eye. The common symptoms include dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired colour vision, or vision loss.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the market is segmented into:
- Proliferative Diabetic Retinopathy
- Non-proliferative diabetic retinopathy
Based on treatment type, the market is divided into:
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- Vitrectomy
The end use of the market include the following:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centres
The regional markets for the diabetic retinopathy treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Cases of Diabetes Augmenting the Market Growth
Diabetes causes damage to the eyes; thus, the growing cases of diabetes among the world population and the favourable reimbursement policies across the globe are expected to accelerate the market growth in the forecast period of 2023 to 2027. The increased income and avoidance of blindness in patients and the rising global geriatric population will further pave the way for the market's growth. However, factors such as lack of insurance and information regarding the disease are projected to restrain the market growth rate. Also, the favourable government policies to make advanced healthcare services available to the masses and extensive research and development activities are likely to generate various new opportunities that will impact the diabetic retinopathy treatment industry growth in the forecast period. Additionally, the expansion of healthcare infrastructure and the rising demand for early detection technologies are some of the other driving factors for the DR treatment market. The clinical pipeline for DR seems full of promises, with lots of drugs under the umbrella specifically targeting diabetic retinopathy among diabetic patients. Moreover, technological advancements in the ophthalmic surgical and diagnostic instruments will aid the growth of the diabetic retinopathy treatment market during the forecast years.
Key Players in the Market for Global Diabetic Retinopathy Treatment
The report gives a detailed analysis of the following key players in the global diabetic retinopathy treatment industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- ALIMERA SCIENCES, INC.
- Genentech, Inc.
- KalVista Pharmaceuticals, Inc.
- Opthea Limited
- Oxurion NV
- Kubota Pharmaceutical Holdings Co., Ltd.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Diabetic Retinopathy Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Diabetic Retinopathy Treatment Historical Market (2018-2023)
8.3 Global Diabetic Retinopathy Treatment Market Forecast (2024-2032)
8.4 Global Diabetic Retinopathy Treatment Market by Type
8.4.1 Proliferative Diabetic Retinopathy
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Non-proliferative Diabetic Retinopathy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.5 Global Diabetic Retinopathy Treatment Market by Treatment Type
8.5.1 Anti VEGF Drug
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Steroid Implants
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Laser Surgeries
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Vitrectomy
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.6 Global Diabetic Retinopathy Treatment Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Ophthalmic Clinics
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Ambulatory Surgical Centres
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2023)
8.6.3.3 Forecast Trend (2024-2032)
8.7 Global Diabetic Retinopathy Treatment Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 ALIMERA SCIENCES, INC.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Genentech, Inc.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 KalVista Pharmaceuticals, Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Opthea Limited
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Oxurion NV
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Kubota Pharmaceutical Holdings Co., Ltd.
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Diabetic Retinopathy Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Diabetic Retinopathy Treatment Historical Market: Breakup by Type (USD Billion), 2018-2023
3. Global Diabetic Retinopathy Treatment Market Forecast: Breakup by Type (USD Billion), 2024-2032
4. Global Diabetic Retinopathy Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2018-2023
5. Global Diabetic Retinopathy Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2024-2032
6. Global Diabetic Retinopathy Treatment Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Global Diabetic Retinopathy Treatment Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Global Diabetic Retinopathy Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Diabetic Retinopathy Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Diabetic Retinopathy Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Diabetic Retinopathy Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Diabetic Retinopathy Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Diabetic Retinopathy Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Diabetic Retinopathy Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Diabetic Retinopathy Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Diabetic Retinopathy Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Diabetic Retinopathy Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Diabetic Retinopathy Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Diabetic Retinopathy Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Diabetic Retinopathy Treatment Market Structure
Key Questions Answered in the Report
In 2021, the global attained a value of nearly USD 5.7 billion.
The market is projected to grow at a CAGR of 6.70% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 8.41 billion by 2027.
The major drivers of the market include the large patient pool, rising disposable income, favourable government policies, extensive research and development activities, expansion of healthcare infrastructure, rising demand for early detection technologies, and technological advancements.
Growing cases of diabetes and rising global geriatric population are the key market trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of diabetic retinopathy treatments are proliferative diabetic retinopathy and non-proliferative diabetic retinopathy.
Based on treatment type, the market is divided into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy.
The end uses of the market include hospitals, ophthalmic clinics, and ambulatory surgical centres.
The major players in the market are ALIMERA SCIENCES, INC., Genentech, Inc., KalVista Pharmaceuticals, Inc., Opthea Limited, Oxurion NV, and Kubota Pharmaceutical Holdings Co., Ltd., among others.
Analyst Review
The global diabetic retinopathy treatment market attained a value of USD 5.7 billion in 2021, driven by the growing cases of diabetes. Aided by the rising demand for early detection technologies and rising geriatric population, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 6.70%. The market is projected to reach USD 8.41 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different types of diabetic retinopathy treatments include proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Based on treatment type, the market is divided into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The end uses of the market are hospitals, ophthalmic clinics, and ambulatory surgical centres. The major regional markets for diabetic retinopathy treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are ALIMERA SCIENCES, INC., Genentech, Inc., KalVista Pharmaceuticals, Inc., Opthea Limited, Oxurion NV, and Kubota Pharmaceutical Holdings Co., Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER